Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- APLI.TO
- Price
- 0.04
- Stock movement up
- +- (%)
- Company name
- Appili Therapeutics Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 4.24M
- Ent værdi
- 18.56M
- Pris/omsætning
- 5.13
- Pris/bog
- -
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -38.43%
- 1 års afkast
- -
- 3 års afkast
- -33.68%
- 5 års afkast
- -45.23%
- 10 års afkast
- -
Senest opdateret: 2025-01-02
UDBYTTE
APLI.TO betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 5.13 |
| Pris til egenkapital | - |
| EV i forhold til salg | 22.43 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 121.27M |
| EPS (TTM) | -0.03 |
| FCF pr. aktie (TTM) | -0.01 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 827.41K |
| Bruttofortjeneste (TTM) | 813.99K |
| Driftsindkomst (TTM) | -5.46M |
| Nettoindkomst (TTM) | -3.82M |
| EPS (TTM) | -0.03 |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 98.38% |
| Driftsmargin (TTM) | -660.16% |
| Fortjenstmargin (TTM) | -461.35% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 301.26K |
| Nettotilgodehavender | 1.79M |
| Omsætningsaktiver i alt | 2.21M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 2.23M |
| Kreditor | 4.52M |
| Kortfristet/nuværende langsigtet gæld | 10.05M |
| Summen af kortfristede forpligtelser | 13.77M |
| Sum gæld | 14.62M |
| Aktionærernes egenkapital | -12.39M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -608.51K |
| Investeringsudgifter (TTM) | 0.00 |
| Fri pengestrøm (TTM) | -608.51K |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | - |
| Afkast af aktiver | -170.94% |
| Afkast af investeret kapital | 163.54% |
| Kontant afkast af investeret kapital | 26.07% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.04 |
| Daglig høj | 0.04 |
| Daglig lav | 0.04 |
| Daglig volumen | 0K |
| Højeste gennem alle tider | 1.87 |
| 1 års analytiker estimat | 0.15 |
| Beta | 0.97 |
| EPS (TTM) | -0.03 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 11 Feb 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| APLI.TO | S&P500 | |
| Nuværende prisfald fra top notering | -98.13% | -3.58% |
| Højeste prisfald | -98.66% | -56.47% |
| Højeste efterår dato | 9 Oct 2024 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -71.95% | -11.12% |
| Gennemsnitlig tid til nyt højdepunkt | 66 days | 12 days |
| Maks. tid til nyt højdepunkt | 1160 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
4.24M
Markedsværdi kategori
Small-cap
Beskrivelse
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Personale
0
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Canada
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
MOUNTAIN VIEW, Calif., December 12, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced ...
12. december 2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFA...
19. november 2024
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal mo...
14. november 2024
MOUNTAIN VIEW, Calif., November 08, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided a...
8. november 2024
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif., November 07, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today shared an ...
7. november 2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: ...
6. november 2024
MOUNTAIN VIEW, Calif., November 06, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today ...
6. november 2024
MOUNTAIN VIEW, Calif., October 31, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today shared an i...
31. oktober 2024
Appili Therapeutics Announces "Alignment" with FDA on ATI-1801 Development Requirements
31. oktober 2024
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the N...
31. oktober 2024
Næste side